Artiva Biotherapeutics Insider Sales: Routine RSU Cover, Not a Signal of Trouble
Insider sales at Artiva Biotherapeutics reveal routine tax‑cover actions tied to RSU vesting, not a sign of trouble, and the company’s strong NK‑cell pipeline and market traction remain intact.
3 minutes to read
